Five drugs were recalled in May to protect patients from possible harmful defects associated with the products, the U.S. Food and Drug Administration reported.
Such recalls are voluntary actions carried out by drug makers to remove potentially defective medicines from the market, the FDA said. They may be initiated either by the manufacturer or the FDA.
Drug Recalls for May
|Date||Brand Name||Product Description||Reason/ Problem||Company|
|May 29||Pecgen DMX,||PECGEN DMX, 16 oz., liquid cough syrup||Mislabeling||NOVIS PR LLC|
|May 28||Heritage||Amikacin Sulfate Injection, USP, 1g/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL)||Potential Lack of Sterility||Heritage Pharmaceuticals Inc.|
|May 11||Promacta||Promacta 12.5 mg oral suspension||Potential Foreign Material||Novartis|
|May 3||Heritage||Losartan Potassium Tablets USP||Defect||Vivimed|
|May 1||Par Pharmaceutical||Mycophenolate Mofetil for injection||Potential Foreign Material||Par Pharmaceutical Inc.|